Sidoti Upgrades Prestige Consumer Healthcare (NYSE:PBH) to Buy

Key Points

• Analysts at Sidoti have upgraded Prestige Consumer Healthcare's rating from neutral to buy, with a target price of $80.00, indicating a potential upside of 27.04% from its previous close.
• The stock is currently rated as a Moderate Buy by analysts, with a consensus target price averaging $94.80 despite recent mixed reviews from other brokerage firms.
• Prestige Consumer Healthcare missed its quarterly earnings estimates, reporting $0.95 EPS compared to the expected $1.01, leading to a 6.6% decline in year-over-year revenue.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was upgraded by analysts at Sidoti from a "neutral" rating to a "buy" rating in a research report issued on Wednesday, MarketBeat reports. The brokerage currently has a $80.00 target price on the stock. Sidoti's price objective would suggest a potential upside of 27.04% from the stock's previous close.

A number of other analysts have also recently weighed in on the company. Canaccord Genuity Group reduced their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Zacks Research cut Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $94.80.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $62.97 on Wednesday. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 14.78, a PEG ratio of 2.01 and a beta of 0.46. The stock's fifty day simple moving average is $68.57 and its 200 day simple moving average is $78.09. Prestige Consumer Healthcare has a 52-week low of $61.93 and a 52-week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $1.01 by ($0.06). The business had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's quarterly revenue was down 6.6% on a year-over-year basis. During the same period last year, the business earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. UMB Bank n.a. lifted its position in Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company's stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock worth $26,000 after acquiring an additional 250 shares during the last quarter. Maseco LLP acquired a new stake in Prestige Consumer Healthcare during the second quarter worth approximately $27,000. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare during the first quarter worth approximately $38,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $46,000. Institutional investors own 99.95% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.